[{"address1": "10628 Science Center Drive", "address2": "Suite 250", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 900 2660", "website": "https://arcturusrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.", "fullTimeEmployees": 174, "companyOfficers": [{"maxAge": 1, "name": "Mr. Joseph E. Payne M.Sc.", "age": 52, "title": "Founder, President, CEO & Director", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 1062000, "exercisedValue": 0, "unexercisedValue": 2086450}, {"maxAge": 1, "name": "Dr. Padmanabh  Chivukula Ph.D.", "age": 45, "title": "Founder, Chief Scientific Officer, COO & Secretary", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 778000, "exercisedValue": 0, "unexercisedValue": 1370925}, {"maxAge": 1, "name": "Mr. Andrew H. Sassine MBA", "age": 60, "title": "CFO & Director", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 811000, "exercisedValue": 0, "unexercisedValue": 1901388}, {"maxAge": 1, "name": "Mr. Lance  Kurata", "title": "Chief Legal Officer", "fiscalYear": 2024, "totalPay": 680000, "exercisedValue": 0, "unexercisedValue": 3125}, {"maxAge": 1, "name": "Ms. Neda  Safarzadeh", "title": "Vice President and Head of IR/PR & Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Natasha O. Bowman", "title": "Chief Human Resources Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin T. Skol", "title": "Chief Business Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juergen  Froehlich FCPh, M.D., MBA", "age": 68, "title": "Chief Medical Officer", "yearBorn": 1956, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Igor  Smolenov M.D., Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Roberta  Duncan", "title": "Chief Strategy Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 3, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 11.91, "open": 13.02, "dayLow": 12.05, "dayHigh": 12.93, "regularMarketPreviousClose": 11.91, "regularMarketOpen": 13.02, "regularMarketDayLow": 12.05, "regularMarketDayHigh": 12.93, "payoutRatio": 0.0, "beta": 2.291, "forwardPE": -5.735426, "volume": 549209, "regularMarketVolume": 549209, "averageVolume": 445906, "averageVolume10days": 528640, "averageDailyVolume10Day": 528640, "bid": 9.21, "ask": 15.48, "bidSize": 2, "askSize": 2, "marketCap": 346872480, "fiftyTwoWeekLow": 8.04, "fiftyTwoWeekHigh": 34.17, "priceToSalesTrailing12Months": 2.4142015, "fiftyDayAverage": 11.4804, "twoHundredDayAverage": 16.49985, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 172582512, "profitMargins": -0.47467, "floatShares": 24984584, "sharesOutstanding": 27120600, "sharesShort": 5413853, "sharesShortPriorMonth": 5071698, "sharesShortPreviousMonthDate": 1744675200, "dateShortInterest": 1747267200, "sharesPercentSharesOut": 0.1996, "heldPercentInsiders": 0.07887, "heldPercentInstitutions": 0.92382, "shortRatio": 12.75, "shortPercentOfFloat": 0.30879998, "impliedSharesOutstanding": 27120600, "bookValue": 8.619, "priceToBook": 1.4839308, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -68200000, "trailingEps": -2.52, "forwardEps": -2.23, "lastSplitFactor": "1:7", "lastSplitDate": 1510790400, "enterpriseToRevenue": 1.201, "enterpriseToEbitda": -2.195, "52WeekChange": -0.5989338, "SandP52WeekChange": 0.119305134, "quoteType": "EQUITY", "currentPrice": 12.79, "targetHighPrice": 140.0, "targetLowPrice": 32.0, "targetMeanPrice": 66.801, "targetMedianPrice": 55.5, "recommendationMean": 1.27273, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 10, "totalCash": 216948000, "totalCashPerShare": 7.999, "ebitda": -78642000, "totalDebt": 42658000, "quickRatio": 4.686, "currentRatio": 5.643, "totalRevenue": 143680000, "debtToEquity": 18.249, "revenuePerShare": 5.31, "returnOnAssets": -0.13668999, "returnOnEquity": -0.27403998, "grossProfits": -32796000, "freeCashflow": -53719876, "operatingCashflow": -89328000, "revenueGrowth": -0.227, "grossMargins": -0.22826, "ebitdaMargins": -0.54734004, "operatingMargins": -0.57265997, "financialCurrency": "USD", "symbol": "ARCT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Arcturus Therapeutics Holdings Inc.", "postMarketChangePercent": 1.17279, "postMarketPrice": 12.94, "postMarketChange": 0.15, "regularMarketChange": 0.88, "regularMarketDayRange": "12.05 - 12.93", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 445906, "fiftyTwoWeekLowChange": 4.75, "fiftyTwoWeekLowChangePercent": 0.590796, "fiftyTwoWeekRange": "8.04 - 34.17", "fiftyTwoWeekHighChange": -21.379997, "fiftyTwoWeekHighChangePercent": -0.625695, "fiftyTwoWeekChangePercent": -59.893383, "dividendDate": 1510790400, "earningsTimestamp": 1747080060, "earningsTimestampStart": 1754305140, "earningsTimestampEnd": 1754654400, "earningsCallTimestampStart": 1747081800, "earningsCallTimestampEnd": 1747081800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.52, "epsForward": -2.23, "epsCurrentYear": -3.50571, "priceEpsCurrentYear": -3.6483338, "marketState": "CLOSED", "shortName": "Arcturus Therapeutics Holdings ", "fiftyDayAverageChange": 1.3095999, "fiftyDayAverageChangePercent": 0.114072666, "twoHundredDayAverageChange": -3.7098494, "twoHundredDayAverageChangePercent": -0.2248414, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1369229400000, "regularMarketChangePercent": 7.38875, "regularMarketPrice": 12.79, "corporateActions": [], "postMarketTime": 1749253180, "regularMarketTime": 1749240001, "exchange": "NGM", "messageBoardId": "finmb_235062181", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Arcturus Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-06-07"}]